Alaunos Therapeutics Inc (TCRT)
2.40
-0.04
(-1.64%)
USD |
NASDAQ |
Nov 13, 16:00
2.41
+0.01
(+0.42%)
After-Hours: 20:00
Alaunos Therapeutics Research and Development Expense (Quarterly): 0.18M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.18M |
| March 31, 2024 | 0.126M |
| December 31, 2023 | 0.933M |
| September 30, 2023 | 3.656M |
| June 30, 2023 | 5.186M |
| March 31, 2023 | 6.504M |
| December 31, 2022 | 5.607M |
| September 30, 2022 | 7.893M |
| June 30, 2022 | 5.937M |
| March 31, 2022 | 5.58M |
| December 31, 2021 | 8.216M |
| September 30, 2021 | 14.52M |
| June 30, 2021 | 13.57M |
| March 31, 2021 | 13.34M |
| December 31, 2020 | 13.97M |
| September 30, 2020 | 13.97M |
| June 30, 2020 | 12.05M |
| March 31, 2020 | 12.71M |
| December 31, 2019 | 10.22M |
| September 30, 2019 | 8.641M |
| June 30, 2019 | 9.998M |
| March 31, 2019 | 9.476M |
| December 31, 2018 | 8.199M |
| September 30, 2018 | 8.263M |
| June 30, 2018 | 7.489M |
| Date | Value |
|---|---|
| March 31, 2018 | 10.18M |
| December 31, 2017 | 11.18M |
| September 30, 2017 | 11.10M |
| June 30, 2017 | 10.83M |
| March 31, 2017 | 11.97M |
| December 31, 2016 | 9.389M |
| September 30, 2016 | 8.975M |
| June 30, 2016 | 129.23M |
| March 31, 2016 | 10.20M |
| December 31, 2015 | 8.142M |
| September 30, 2015 | 16.97M |
| June 30, 2015 | 7.424M |
| March 31, 2015 | 74.25M |
| December 31, 2014 | 8.085M |
| September 30, 2014 | 9.733M |
| June 30, 2014 | 8.346M |
| March 31, 2014 | 6.542M |
| December 31, 2013 | 2.719M |
| September 30, 2013 | 6.247M |
| June 30, 2013 | 14.78M |
| March 31, 2013 | 19.11M |
| December 31, 2012 | 34.98M |
| September 30, 2012 | 16.22M |
| June 30, 2012 | 18.26M |
| March 31, 2012 | 13.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.126M
Minimum
Mar 2024
14.52M
Maximum
Sep 2021
8.114M
Average
7.893M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 9.275M |
| Oragenics Inc | 0.9068M |
| Cocrystal Pharma Inc | 4.308M |
| Cara Therapeutics Inc | 9.308M |
| Jaguar Health Inc | 3.653M |